EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
By T. Shibue, R. Weinberg. Nature Reviews Clinical Oncology, 2017
2,297 citations recorded by the source corpus.
The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity — that is, the phenotypic diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely capable of seeding new tumours, has provided a framework for understanding one dimension of intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic basis for anticancer drug resistance. In fact, accumulating evidence indicates that conventional therapies often fail to eradicate carcinoma cells that have entered the CSC state via activation of the EMT programme, thereby permitting CSC-mediated clinical relapse. In this Review, we summarize our current understanding of the link between the EMT programme and the CSC state, and also discuss how this knowledge can contribute to improvements in clinical practice.
Subfields: Mechanical Engineering, Metals and Alloys
View Paper: https://www.semanticscholar.org/paper/464a2da269ed1f6c0150ac7aafcb855aacaa2f68
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Mechanical Engineering
In Metals and Alloys
Citations in the corpus
- Dynamic EMT: a multi‐tool for tumor progression (2021, positive): “Strikingly, tumor initiation capacity is increasing with EMT activation by stem cell features provided by EMT-TFs within the cell plasticity window (Puisieux et al , 2014; Nieto et al , 2016; Shibue & Weinberg, 2017; Wilson et al , 2020) (Fig 3).”
- PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “pathways [357, 358], and cellular plasticity [359, 360] can contribute to drug tolerance (Supplementary information 3).”
- Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020, background): “While the link between EMT and drug resistance is well established (Shibue and Weinberg, 2017), our CRISPR screen provided functional evidence for several integrin-related genes, whichmay represent additional druggable vulnerabilities.”
- Drug resistance and combating drug resistance in cancer (2019, background): “Understanding the mechanistic linkage between EMT, CSC and drug resistance would significantly contribute to anticancer therapeutics([130]).”
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation (2018, background): “…more likely to result in cancer cell spread to distant organs, causing disease progression and poor prognosis, particularly because metastases are usually resistant to available therapies (Friedmann-Morvinski and Verma, 2014; Ge et al., 2017; Shibue and Weinberg, 2017; Visvader and Lindeman, 2012).”